After FDA Requests More Data On COVID-19 Treatment
Post# of 153802
(Total Views: 754)
Posted On: 09/25/2020 6:54:56 PM
After FDA Requests More Data On COVID-19 Treatment, This Analyst Remains Sidelined
... On top of this, in July, CytoDyn received a Refuse to File (RTF) letter from the FDA regarding its Biologics License Application (BLA) for leronlimab as a combination therapy with highly active anti-retroviral therapy (HAART) for highly treatment-experienced HIV patients. While the company now has all of the required data and is compiling the data package, management has not disclosed a time frame for the BLA resubmission.
Based on all of the above, Chen maintained his Neutral (i.e. Hold) rating on CYDY shares. Given the market valuation and volatility, the analyst doesn’t attach a specific price target. (To watch Chen’s track record, click here)
https://www.tipranks.com/news/article/cytodyn...sidelined/
Sorry if posted already ...
... On top of this, in July, CytoDyn received a Refuse to File (RTF) letter from the FDA regarding its Biologics License Application (BLA) for leronlimab as a combination therapy with highly active anti-retroviral therapy (HAART) for highly treatment-experienced HIV patients. While the company now has all of the required data and is compiling the data package, management has not disclosed a time frame for the BLA resubmission.
Based on all of the above, Chen maintained his Neutral (i.e. Hold) rating on CYDY shares. Given the market valuation and volatility, the analyst doesn’t attach a specific price target. (To watch Chen’s track record, click here)
https://www.tipranks.com/news/article/cytodyn...sidelined/
Sorry if posted already ...
(0)
(0)